Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gardasil

Merck Stock Reverses, Though Gardasil 'Woes' Continue In China, Japan

Merck stock reversed higher Thursday, though the company reported another quarter of light sales for its HPV vaccine, Gardasil.

Investors Business Daily

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

MarketBeat

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

How RFK Jr. drove mistrust of a cancer prevention vaccine - Roll Call

President-elect Donald Trump's pick to lead HHS has a long history of discounting and peddling misinformation about the HPV vaccine.

Roll Call

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Merck Outplays The Covid Decline, But Prometheus Buyout Weighs On Profits

Merck topped second-quarter expectations Tuesday, though it reported a per-share loss. Merck stock toed the line in response.

Investors Business Daily

Merck Reverses Higher As Keytruda, Gardasil Outplay Covid Decline; Bristol Shares Dip

Merck topped forecasts Thursday while Bristol Myers delivered a mixed performance. Merck stock swung to a gain while and BMY stock fell.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products. Pharmaceutical sales growth, excluding Lagevrio sales, was…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Children Health Defense

27 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.